Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

1-1-1.jpg

April 25, 2018 OrthoSpineNews

EDISON, N.J.April 25, 2018 /PRNewswire/ — MTF Biologics Wound Care has expanded its portfolio of innovations with AmnioBand® Viable Membrane, an aseptically processed and cryopreserved human amnion membrane for use as an acute or chronic wound covering. MTF Biologics Wound Care will feature the novel tissue graft at the Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) meeting held at the Charlotte Convention Center in Charlotte, N.C.April 25-29, 2018.

In addition to introducing AmnioBand® Viable Membrane at the meeting, MTF Biologics Wound Care will host a symposium on outcomes for placental and dermal innovations in wound care, and its tissue grafts will be featured in three poster presentations.  It also will announce new support for SAWC’s 2018 Martin Salia Scholarship Fund.

“Wounds remain a significant challenge for the healthcare community,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “More than six million Americans will struggle with chronic non-healing wounds this year alone. AmnioBand® Viable Membrane is an important new option for clinicians working to heal difficult wounds of all kinds. Leveraging our 20 years of processing and providing living cell tissue forms, and recognizing that there is no single solution in wound care, we continue to deliver on our mission of honoring the donated gift, serving patients, and advancing science by releasing the next generation living allograft placental matrix.”

recent study published by Matthew Regulski, DPM, in Wounds titled, “Utilization of Viable Human Amnion Membrane Allograft in Elderly Patients with Chronic Lower Extremity Wounds of Various Etiologies,” demonstrates the potential for AmnioBand® Viable Membrane to help the closure of non-healing wounds in elderly patients with multiple comorbidities.

“We are dedicated to innovation in allograft science to improve clinical outcomes and support healthcare providers,” said Marc Long, PhD, Vice President of R&D at MTF Biologics. “We ensure that each AmnioBand® Viable donation is tested for viability, offer the tissue with an intelligent colorimetric change to indicate graft readiness, and provide the graft on a flexible backing for an enhanced yet intuitive clinical application. Processing and quality matters, and we are excited to showcase the translation of our scientific development with our proven clinical results.”

MTF Biologics has provided a grant to HMP, a leading healthcare events and education company, and organizers of the annual SAWC Spring and Fall meetings. The funding will be used to support the 2018 Martin Salia Scholarship Fund giving surgical residents from the Pan-African Academy of Christian Surgeons (PAACS) the opportunity to participate in the 2018 SAWC Fall meeting, taking place November 2-4, 2018, in Las Vegas, Nevada. The program is named in memory of Dr. Martin Salia, a graduate of the PAACS program. Dr. Salia was one of 136 physicians treating a population of 6 million in Sierra Leone when he contracted the Ebola virus and died in November of 2014.

“Access to advanced wound care therapies is limited in many rural African communities,” said Jeffrey Cartmell, PhD, Associate Director of Intellectual Property and Grants at MTF Biologics. “We are committed to the evidence-based education that recipients of the Martin Salia Scholarship will receive at SAWC. We are honored to play a role in assisting these physicians as they seek to improve their ability to care for the patients in their communities.”

MTF Biologics’ symposium, “Level 1 Clinical Outcomes for Placental & Dermal Innovations,” will feature perspective on recently published Level 1 clinical outcomes for aseptically processed placental and dermal innovations from Dennis Orgill, MD, PhD, Charles Zelen, DPM, FACFAS, Lawrence DiDomenico, DPM, FACFAS, and Jarrod P. Kaufman, MD, FACS. The complimentary lunch symposium will be held in Room 217D on Thursday, April 26, from 12 p.m. – 1:30 p.m. Onsite registration will be available.

Additional clinical & scientific poster presentations at the meeting will include:

  • The Safety, Efficacy, and Cost to Closure of a Unique Aseptically Processed Dehydrated Allogeneic Amnion and Chorion graft versus Standard of Care in the Treatment of Chronic Diabetic Foot Ulcers: A Prospective, Randomized, Controlled, Multi-centre Trial – DiDomenico et al. Abstract: CR-007
  • Preliminary Observations on the Mechanism of Viable Human Amnion Membrane Allograft* in the Diabetic Wound, using the db/db Mouse Splinted Excisional Wound Model – Xie et al. Abstract: LR -076
  • Aseptically Processed Dehydrated Human Amnion/Chorion Allografts Restores Type II Diabetic Cell-Mediated Granulation, Angiogenesis and Epithelialization Activities that Support Wound Healing – Dasgupta et al. Abstract: LR-014

About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of clinicians who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 125,000 donors and distributed more than 8 million grafts for transplantation. Through its IIAM subsidiary, it has placed more than 55,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 10 million donor referrals. For more information, visit www.mtfbiologics.org.

SOURCE MTF Biologics

Related Links

https://www.mtf.org


K2M-OSN-002-12-5.jpg

April 25, 2018 OrthoSpineNews

Good morning Lane, thank you for taking some time to talk with us this morning. If you wouldn’t mind introducing yourself to our readers and telling us a bit about your background to get started…

Sure thing, Mason. I truly appreciate the opportunity to share our K2M story with you. I have spent my entire career in the spinal devices space, beginning with a field-based role in Northern Virginia carrying primarily Stryker products. I was also exposed to several Globus products and some osteobiologics. Being in the operating room each day gave me a strong foundation in the spine industry. One that I keep with me today.

In January 2004, K2M was founded with a vision of improving the lives of people across the world with spinal deformities. I’ve been with the company ever since and am grateful for the work we do each day.

Thanks for that background, Lane. What is your biggest motivator for coming into work every day at K2M? 

When you are with a company that changes lives—particularly for children suffering from scoliosis—seeing the positive impact of our work is all that matters. The societal value we create has resulted in a corporate culture second to none. It’s something you feel when you walk through the door. We hear this all the time from surgeons and others who visit us from around the world.

Our commitment to social good begins in Loudoun County, VA—our global headquarters—as well as at a national and global level. One example is a program called Straight 2 Swimming. Just imagine children with scoliosis who never could swim because they’re embarrassed to take off their shirts. We help them build confidence; it’s a huge motivator for me. Another example is the FOCOS Hospital we helped found in Ghana. The fact that our products are used to treat the world’s most challenging deformity cases inspires us each day.

Wow, that is incredible, Lane. Thank you for sharing that with us. Furthermore, can you give us an overview of the various 3D Solutions K2M offers and how you first got into the space?

Absolutely. K2M is leading the way in the 3D printing of spinal devices. But this work started well before 3D printing became popular. It came about because we were seeking to overcome a challenge.

Because our products are used in 40 different countries around the world, we have gained valuable insights from surgeons on what tools they need to improve outcomes in patients. Years ago, we began hearing people talking about how there should be a better alternative to PEEK implants. So, we partnered with a team of global key opinion leaders to create the Alternative Materials Design Team. The design input from this team led us to solutions that simply couldn’t be manufactured traditionally. It required innovation.

To improve upon PEEK technology, we partnered with 3D Systems—the world’s foremost leader in 3D printing for medical purposes. Today, we have a world-class portfolio of 3D-printed devices that address a diverse range of degenerative, complex spine, and MIS procedures. All of which feature our innovative Lamellar 3D Titanium Technology™, which uses an advanced 3D-printing method to create structures that were once considered impossible with traditional manufacturing. It allows us to develop devices with a porosity and surface roughness that pre-clinical data have associated with bone growth activity, as well as a decreased radiographic signature. All of which help improve outcomes in patients undergoing spine surgery.

Having said that, what is your vision for where the company goes from here?

Our vision is to be the leader in complex spine and minimally invasive solutions. We have had consistently strong success in these areas, and today, patients and physicians are asking us to help in the other areas of treatment. Therefore, we are introducing new technologies—such as our Balance ACS® (BACS) platform—to help surgeons and patients in all phases of preoperative, intraoperative, and postoperative patient care. Balance ACS is game-changing, as it uses a 360-degree approach to the axial, coronal and sagittal planes so surgeons can take a more holistic and comprehensive approach to treatment. It also includes a suite of data management software that lets surgeons collect and analyze patient data to improve treatment.

As we move forward, we will continually find ways to drive costs down for the patient, make practices more intuitive for surgeons, ensure faster recovery time, and much more.

We are really looking forward to seeing everything that lies ahead for K2M. Can you leave us with some closing remarks or any predictions about the spine industry as a whole? 

There remains a significant opportunity for innovation in the spinal devices space. K2M is at the forefront of inventing solutions for the full continuum of care, not just limited to implants and instrumentation. The opportunity for innovation remains robust; we believe that K2M is well-positioned to position to continue leading.

Well Lane we really appreciate you taking the time to chat with us today. It was great to get some insights into the K2M story as well as what’s on the horizon. We wish you all the best moving forward. 

Thanks Mason, likewise. We really appreciate the opportunity. Take care.


guilty-verdict-1-1.jpg

April 25, 2018 OrthoSpineNews

Walter Eisner • Tue, April 17th, 2018

Daniel Lawrynowicz, a former Stryker Corporation engineering director, plead guilty on April 3, 2018 to accepting a $75,000 bribe for steering business to a New York metallurgy firm.

According to the Department of Justice (DoJ), Lawrynowicz, 48, pleaded guilty before U.S. District Judge Madeline Cox Arleo in Newark federal court to an information charging him with one count of violating the Federal Travel Act.

According to DOJ documents, in 2012, while Lawrynowicz was an employee of Stryker, Eugene Ostrovsky and two other individuals at Sanova LLC, sought a contract worth $5.5 million with Stryker. Lawrynowicz was in a position to make recommendations to others at Stryker related to the goods that Sanova sought to supply under the contract.

“Ostrovsky and the other individuals made illicit bribe payments to Lawrynowicz in exchange for his assistance in helping the technology company secure the contract with the medical device company. These payments included a cash payment of approximately $75,000 to Lawrynowicz after the contract between the two companies was signed.”

Sanova VP Pleads Guilty

In February, Ostrovsky, a vice president and partner at Sanova LLC, pleaded guilty to bribing Lawrynowicz in 2012 and 2013 to win the $5.5 million contract with Stryker. He was sentenced March 9 to six months in jail, six months of home confinement and two years of supervised release. Prosecutors said Ostrovsky will also forfeit $1.1 million.

Lawrynowicz’s LinkedIn page listed him as a 15-year Stryker employee who was senior director of advanced engineering, leading “a team of 41 engineers and scientists at the Mahwah, N.J. facility dedicated to supporting the Recon Business Units.”

The U.S. Patent and Trademark Office lists at least half a dozen patents filed by Daniel Lawrynowicz, of Monroe, along with others, between 2010 and 2013, while he worked for Howmedica Osteonics Corp., of Mahwah.

Jeanine Guilfoyle, a spokeswoman for Stryker, reportedly said the company would not comment on the case or Lawrynowicz’s employment at the company.

 

READ THE REST HERE


2217-AB-1.jpg

April 25, 2018 OrthoSpineNews

April 25, 2018

DUBLIN–(BUSINESS WIRE)–The “North America Minimally Invasive Surgical Instruments Market – Forecasts from 2018 to 2023”report has been added to ResearchAndMarkets.com’s offering.

North America minimally invasive surgical instruments market is projected to grow at a CAGR of 7.28% from a market size of US$6.954 billion in 2017 during the forecast period and reach a market size of US$10.601 billion in 2023.

Early adoption of advanced technologies coupled with the presence of major market players in the region contributes to the growth of North America minimally invasive surgical instruments market. Growing geriatric population and high demand for quality healthcare services in this region further supports the market growth of minimally invasive surgical instruments market in the region.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Companies Mentioned

  • Ethicon US, LLC
  • Aesculap, Inc.
  • Medtronic
  • Stryker
  • Zimmer Biomet
  • CONMED Corporation
  • Microline Surgical
  • Abbott Laboratories

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

5. North America Minimally Invasive Surgical Instruments Market By Type

6. North America Minimally Invasive Surgical Instruments Market By Application

7. North America Minimally Invasive Surgical Instruments Market By Geography

8. Competitive Intelligence

9. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/kh8zg4/north_america?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Surgical Devices


David_Castleman-123-1.jpg

April 25, 2018 OrthoSpineNews

April 25, 2018

ST. LOUIS–(BUSINESS WIRE)–CoreLink, LLC, a fast growing, vertically integrated designer and manufacturer of spinal implant systems, announced today the recent appointment of David Castleman to the newly created position of Vice President of Research and Development.

“CoreLink draws on nearly half a century of surgical device manufacturing expertise. When combined with our robust internal capabilities, we are now well positioned to develop a wide array of new products to advance the state of spine care,” said Jay Bartling, founder and CEO of CoreLink, LLC. “We are excited to create this new position and believe David to be the perfect candidate for it. His engineering insight and product development rigor will help focus and leverage our capabilities in pursuit of our commitment to empower our surgeons’ performance and help improve their patients’ lives.”

Under the product development leadership of Mr. Castleman, CoreLink expects to launch multiple new implant systems in 2017 including a full direct lateral platform of products, Foundation™ 3D ALIF*, M3™ Stand-alone ALIF*, and Foundation Corpectomy*, all of which will feature the patent pending Mimetic Metal™ and StrutSure™ 3D printed titanium technologies. (*Not currently available for sale in the United States)

“I am pleased to join such a young and nimble yet broadly capable company,” said Castleman. “The vertical integration of CoreLink’s manufacturing provides significant advantages with regard to product development. The more intimate working relationship between engineering and manufacturing not only enhances its speed to market, but also facilitates better quality control and product improvement. We are going to make some great stuff.”

David adds more than 25 years of orthopedic device experience including 14 years in the spine industry. He gained expertise in international business development, marketing, and product development in positions with Smith & Nephew, Medtronic, and Zimmer Biomet, respectively. David received his Master of Business Administration from the University of Memphis and a Bachelor of Science degree in Mechanical Engineering from the University of Tennessee.

For more information, visit: www.corelinksurgical.com

About CoreLink

CoreLink, LLC internally designs and manufactures more than 99% of its broad portfolio of spinal implant systems. CoreLink leverages this expertise through collaboration and a dedication to empowering surgeons with the highest quality and most effective instruments and implants possible. That is how CoreLink came to be known as The Source.

Be a part of something at The Source.

Contacts

CoreLink, LLC
Matthew Linhardt, 888-349-7808
m.linhardt@corelinksurgical.com


slider4_876x300-1.jpg

April 25, 2018 OrthoSpineNews

April 25, 2018

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced that University Orthopedics in Providence, Rhode Island, and the Hey Clinic for Scoliosis and Spine Surgery in Raleigh, NC, have installed the EOS® system for low-dose, 2D and 3D imaging of patients. Both practices are part of the U.S. private practice sector, which amounts to 73 percent of all orthopedic practices in the country.

University Orthopedics is a multiple facility private practice in Rhode Island for patients with orthopedic related conditions and injuries. University Orthopedics directs many clinical research efforts intended to innovate new orthopedic surgery techniques, new surgical implant devices that improve the success of various procedures, and new ways to prevent orthopedic injury.

We believe in using advanced technology to provide the safest and best healthcare possible” said Dr. Alan Daniels, Adult Spine Deformity Orthopedic Surgeon and Partner at University Orthopedics. “EOS® provides extremely high-quality full-body images for pediatric and adult patients at lower radiation doses than traditional x-rays, increasing patient safety. The EOS® images allow us to carefully assess the entire skeleton, so we can provide optimal individualized patient-specific care.”

Weber Shill, CEO of University Orthopedics, added: “I saw the clinical and educational benefits of the EOS® system immediately and was enthusiastic about getting behind a project that our surgeons were so motivated about and I knew our patients would appreciate. Like any healthcare organization today, we have to be cognizant about our capital expenditures, and EOS imaging custom finance program for the private sector facilitated our acquisition.”

For more than 13 years, the Hey Clinic has served patients with spinal conditions from North Carolina and beyond through a full array of treatment options. The clinic, recently relocated to a new facility on the Duke Raleigh Hospital campus, is committed to personalized attention, generous appointment times and a strong emphasis on patient education and engagement.

“When we decided to update our imaging options, we thoroughly researched available technologies and determined that the EOS® system would best serve our patients with its high image quality for diagnostics, low radiation to decrease cancer risk and 3D modeling capabilities for treatment planning,” commented Dr. Lloyd Hey, Orthopedic Surgeon and Founder of the Hey Clinic. “In addition, EOS® will help us facilitate educating patients and families about their condition and treatment choices. We are excited to work with EOS imaging to improve patient care.

“We are encouraged to see a growing number of private practices adopting the EOS® system” said Marie Meynadier, Chief Executive Officer of EOS imaging. “Our technology has received strong recognition from academic and non-academic hospitals, both clinically and in terms of operational value. Private practices play an important role in orthopedic care, and we will do our best to support them in providing our low dose, 2D/3D solutions to a growing number of patients.”

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopaedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Press Relations (US)
Joanna Zimmerman
The Ruth Group
Ph: 646-536-7006
jzimmerman@theruthgroup.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com


3D-Printing-image800-1a-1.jpg

April 25, 2018 OrthoSpineNews

NESS ZIONA, IsraelApril 23, 2018 /PRNewswire/ —

CollPlant (NASDAQ: CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products today announced the opening of a new rhCollagen production facility in Rehovot, Israel.

This 6,000 square foot cGMP facility was designed for purification of rhCollagen and formulation of end-products, including BioInks for 3D bioprinting and its proprietary tissue repair products. The facility includes clean rooms, logistic support areas, and dedicated production equipment to support the company’s production demand for the next few years.

Yehiel Tal, CEO of CollPlant commented: “The new facility will enable operational flexibility and cost reduction for the rhCollagen and end products. Consequently, we believe the new facility will enhance our competitiveness and profitability. Additionally, we expect this facility to serve for process development of new production technologies.”

The first production runs have been successfully completed, and validation is expected to take place during the second quarter of 2018.

About CollPlant

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant’s proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, and our unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

For more information about CollPlant, visit http://www.collplant.com

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Collplant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink, VergenixSTR, and VergenixFG; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based BioInk, VergenixSTR, and VergenixFG; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection we are able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting Collplant is contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other filings that Collplant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and Collplant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:   
Eran Rotem
Deputy CEO and CFO
Tel: + 972-73-2325600/612
Email: Eran@collplant.com

IR Contact 
Amato and Partners, LLC
90 Park Avenue, 17th Floor
New York, NY 10016
admin@amatoandpartners.com

SOURCE CollPlant


navio-li-1.jpg

April 25, 2018 OrthoSpineNews

24 April 2018

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, announces that Spire Bushey Hospital in the UK, has completed Europe’s first robotics-assisted total knee replacement procedure using the NAVIO Surgical System.

Consultant Orthopaedic Surgeon Mr Richard Carrington, MBBS, FRCS (Orth), performed the first surgery using the Smith & Nephew JOURNEY II Total Knee System.

The Smith & Nephew NAVIO Surgical System is a next generation handheld robotics platform designed to aid surgeons with component positioning, ligament balancing and bone preparation – key factors that may drive implant survivorship.1,2  NAVIO is designed to help the surgeon with surgical planning and balancing of the joint to the patient’s specific needs. The handheld instrumentation uses multiple control modes to help the surgeon accurately prepare the bone for implantation.

The small footprint of NAVIO allows for easy set up and portability. Furthermore, NAVIO does not require a preoperative image, such as a CT scan. This allows patients to receive the benefits of robotics-assistance without the extra steps, costs, and radiation associated with additional preoperative imaging.3

“We are proud to support Spire Bushey in being the first hospital in Europe to bring patients the benefits of a robotic-assisted total knee procedure using the NAVIO Surgical System,” said Massimiliano Colella, President Europe and Canada, Smith & Nephew. “It is an important innovation as 80% of all knee replacement surgeries globally are total knees4, and it is exciting that Spire’s patients can now benefit from the improvements in accuracy that robotics is designed to deliver.”

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew plc

References

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

About Spire Bushey Hospital

Working with leading consultants in their field, we have become the private hospital of choice for knee replacements in London and our region. Across both 2016 and 2017*, more knee replacements were carried out at Spire Bushey than any other private London hospital.  Our team of expert physiotherapists provide comprehensive pre-habilitation programmes to help strengthen the limb before surgery to improve recovery. They use the onsite gym and hydrotherapy pool to support patient rehabilitation following surgery.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 


LMASfixcrop2-e1509138763115-1.png

April 24, 2018 OrthoSpineNews

SAN DIEGOApril 24, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company is a sponsor of the American Association of Neurological Surgeons (AANS) Annual Scientific meeting being held April 28-May 2, 2018, in New Orleans, at the Earnest N. Morial Convention Center. NuVasive will host a hands-on workshop featuring the latest advances in Lateral Single-Position surgery, technology to reduce OR radiation and developments in 3D-printed implants.

The NuVasive Industry Lunch and Learn Workshop, Single-Position Lateral Surgery Solutions to Treat L4-S1, Featuring Advanced 3D-Printed Implants and LessRay® Radiation Emission Reduction Technology, by Kaveh Khajavi, M.D., Robert Issacs, M.D. and Juan Uribe, M.D., will take place on Monday, April 30 from 1:10-1:55 p.m. in Room 272-273. For more information, visit the AANS Program Schedule.

“The interactive workshop provides a forum to discover our commitment to Safer, Faster and Smarter surgery through Surgical Intelligence as well as our leadership position in Lateral Single-Position surgery and how it fits in with our industry-leading lateral procedural solutions,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “Lateral Single-Position benefits include reducing the number of times a patient has to be repositioned for greater OR efficiency. Attendees will hear directly from early adopters of the technology and also learn what NuVasive is doing to incorporate advanced materials into its surgical implants and how Surgical Intelligence includes proactively combatting radiation exposure in the OR with LessRay technology.”

Additionally, AANS attendees can visit NuVasive Booth #529 to experience the latest innovative spine solutions and systems firsthand from the NuVasive team of experts and meet NFL great and NuVasive spokesperson Archie Manning. The College Hall of Fame and former NFL Pro Bowl quarterback will discuss his firsthand experience with the life-changing NuVasive XLIF® procedure at the Lunch and Learn and in the booth on Monday, April 30. Manning continues to proudly share his personal story of how the XLIF spine procedure changed his life by restoring height and stability to the collapsed disc space on the left side of his lumbar spine. XLIF is the leading lateral spine procedure, supported by over 10 years of clinical evidence.

Individual NuVasive booth stations will focus on a variety of spine solutions, including Lateral Single-Position Surgery, Surgical Intelligence, Advanced Materials Science™, Cervicothoracic and TLIF.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com


OSC-rings-chris-stewart-4-1200x805.png

April 24, 2018 OrthoSpineNews

Ortho Sales Partners, the global leader in commercialization services for the orthopedic industry, is pleased to announce the addition of Chris Stewart to the companies executive team. Mr. Stewart is a very well regarded leader and innovator that brings an in-depth knowledge of the supplier, hospital and physician relationship. In addition to having a cross functional leadership role, Mr. Stewart will lead the organization and its clients in strategies related to hospital access and supply chain value analysis illustration as well as enhancing Ortho Sales Partners software and logistics platforms developed to optimize supply chain delivery and clinician user experience.

Prior to joining Ortho Sales Partners, Mr. Stewart was the Assistant Vice President and Business Unit Leader of Medical Device Management for HealthTrust. Mr. Stewart managed consulting services for hospital IDN memberships comprised of approximately 1,600 acute and 2,000 ASC facilities. He oversaw a team of orthopedic, spine, osteobiologic and cardiovascular specialists who worked with hospital clients to actively manage their clinically sensitive implant service lines. Using data as an asset, his team developed strategic roadmaps to help hospitals and physicians achieve financial and clinical alignment, so they could plan, not just react, to financial pressures and complex market changes.

Mr. Stewart holds a bachelor’s degree in economics and business administration from the University of Tennessee, Knoxville. He has presented at numerous healthcare forums on topics that include physician engagement, clinical best practice, alternative service models for the OR, strategic alliance of GPOs, shifting reimbursement models, new technologies, changing population demographics and the future of supply chain delivery.

About his new role, Mr. Stewart said: “I am excited to be joining this team of accomplished industry thought leaders who share the same vision and passion for enhancing value within this ever-changing healthcare environment”

Kevin McGann, CEO of Ortho Sales Partners, said: “We are very pleased to announce the addition of Chris Stewart to our team at Ortho Sales Partners.  Chris is a well-respected healthcare executive, who has tremendous knowledge of the hospital networks, ambulatory surgery centers and group purchasing organizations.  His experience in creating value added programs, and the utilization of data to direct purchasing behaviors is a tremendous asset to manufacturers, healthcare providers and physicians across the entire industry”

_____________

About Ortho Sales Partners

Ortho Sales Partners has created a unique platform to help companies in any stage commercialize their products in a very efficient way. We have worked closely with many organizations and produced results that have profoundly impacted each client’s business.

Our services are geared to meet you where you are today and help your business grow by utilizing proven industry executives that bring you an objective analysis and recommendations going forward. Our market knowledge is based on current trends and competitive analysis from industry stalwarts from some of the highest growth companies.

Ortho Sales Partners’ headquarters are in Scottsdale, Arizona but we have several offices across the US. (http://www.orthosalespartners.com).

 

Additional Product Platforms

Surg.io (http://www.surg.io)

OrthoEx (http://www.orthoex.com)

The De Angelis Group (http://www.orthospinesearch.com)